Roivant Sciences Stock Forecast
NASDAQ: ROIVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:15 AM ET
ROIV analyst consensus
Consensus (13 analysts)
strong_buy
Avg. price target
$48.08+39.69%
- Strong buy 2
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 13 Wall Street analysts covering Roivant Sciences (2026-10-07), 12 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $48.08, with a high estimate of $55.00 and a low estimate of $41.00. The average target implies upside of 39.7% from the current price of $34.42.
The spread between the highest and lowest targets is 34.1%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ROIV.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 2 | 15% |
| Buy | 10 | 77% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $41.00 | +19.12% |
| Average target | $48.08 | +39.69% |
| High target | $55.00 | +59.79% |